Beam Therapeutics Inc. announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial. BEAM-302 is being evaluated in an open-label, dose-escalation Phase 1/2 clinical trial that will investigate the safety, pharmacodynamics, pharmacokinetics and efficacy of BEAM-302. The study design includes a dose exploration portion followed by a dose expansion portion to identify the optimal dose to take forward in a pivotal study.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.43 USD | -2.29% | +2.14% | -13.92% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.92% | 1.85B | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- BEAM Stock
- News Beam Therapeutics Inc.
- Beam Therapeutics Inc. Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency